SCHEMBL30009527

SCHEMBL30009527

c1ccc(Cn2cc(-c3ccnc4[nH]ccc34)cn2)cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM4 Q14833 1/20 0.65
CCNK O75909 4/20 0.64
CDK12 Q9NYV4 4/20 0.64
AURKB Q96GD4 3/20 0.60
AURKA O14965 2/20 0.60
INCENP Q9NQS7 2/20 0.60
TPX2 Q9ULW0 2/20 0.60
ALK Q9UM73 2/20 0.58
IKBKB O14920 1/20 0.58
CHUK O15111 1/20 0.58
DAPK3 O43293 1/20 0.58
JAK2 O60674 1/20 0.58
PRKD3 O94806 1/20 0.58
MAP4K4 O95819 1/20 0.58
PAK4 O96013 1/20 0.58
CSF1R P07333 1/20 0.58
RET P07949 1/20 0.58
IGF1R P08069 1/20 0.58
FGFR1 P11362 1/20 0.58
PRKACA P17612 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL99234 1.00 GRM4 (0.65) GRM4CCNKCDK12AURKBAURKA
Trifluoroacetic Acid SCHEMBL4082781 0.91 JAK1 (0.55) GRM4CCNKCDK12AURKBAURKA
SCHEMBL29541183 0.91 CCNK (0.67) GRM4CCNKCDK12AURKBAURKA
SCHEMBL99693 0.91 CCNK (0.67) GRM4CCNKCDK12AURKBAURKA
SCHEMBL100073 0.87 GRM4 (0.55) GRM4CCNKCDK12AURKBAURKA
SCHEMBL16673732 0.86 GRM4 (0.60) GRM4CCNKCDK12AURKBAURKA
SCHEMBL101771 0.85 AURKB (0.54) GRM4CCNKCDK12AURKBAURKA
SCHEMBL99686 0.85 AURKB (0.56) GRM4CCNKCDK12AURKBAURKA
SCHEMBL29540389 0.85 AURKB (0.56) GRM4CCNKCDK12AURKBAURKA
SCHEMBL99272 0.85 GRM4 (0.58) GRM4CCNKCDK12AURKBAURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11524968-B2 Heterocyclic compound as a protein kinase inhibitor HK INNO.N CORPORATION (KR) 2022-12-13 US claimed
US-11524968-B2 Heterocyclic compound as a protein kinase inhibitor HK INNO.N CORPORATION (KR) 2022-12-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11524968-B2 Heterocyclic compound as a protein kinase inhibitor MAP3K20, MAP3K15, MAP3K1 GRM4 1716/4885CCNK 820/4885CDK12 525/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.